<DOC>
	<DOCNO>NCT02416180</DOCNO>
	<brief_summary>This study aim explore potential impact switch inhaler assess handle error rate ( critical non-critical ) control asthmatic currently treat , use correctly , SERETIDE via DISKUS Inhaler switch receive SERETIDE via Metered Dose Inhaler ( MDI ) ( EVOHALER ) without train Healthcare Professional ( HCP ) . This descriptive , multi-centre , open-label , non randomize 14 day study assess MDI technique subject control asthma ( Asthma Control Test [ ACT ] score &gt; = 20 Visit 1 ) currently treat , able use correctly , SERETIDE via DISKUS Inhaler . All eligible subject switch equivalent dose SERETIDE via MDI . Subjects need use MDI inhaler accordance accompany patient information leaflet ( read prior use ) approximately 14 day . No instruction , coach comment inhaler technique provide HCP . MDI technique subject assess Visit 2 ( 14 day ) error record . Subject revert back use SERETIDE DISKUS inhaler Visit 2 . Subjects follow telephone approximately 1 week Visit 2 . A maximum 110 subject enrol approximately 100 evaluable subject complete study . The total duration study subject approximately 21 day . SERETIDE , EVOHALER DISKUS register trademark GlaxoSmithKline ( GSK ) group company</brief_summary>
	<brief_title>Study Evaluate Handling Errors Usage SERETIDE® Metered Dose Inhaler ( MDI ) ( EVOHALER® ) Adult Subjects Currently Using SERETIDE DISKUS® Inhaler</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>&gt; =18 year age time informed consent . A diagnosis asthma define National Institutes Health , 2007 . Must currently treat SERETIDE via DISKUS Inhaler maintain dose 3 month prior Visit 1 . Have control asthma defined total ACT score &gt; = 20 Must able use DISKUS inhaler correctly . Correct use define make critical error assessment DISKUS inhaler use Visit 1 . Male Female subject eligible participate pregnant ( confirm negative urine human chorionic gonadotrophin [ hCG ] test ) , lactate , least one follow condition applies : 1 . Nonreproductive potential define : Premenopausal females one following ; document tubal ligation , document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , hysterectomy , document bilateral Oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] estradiol level consistent menopause ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . 2 . Reproductive potential agrees follow one option list GSK modify list highly effective method avoid pregnancy female reproductive potential ( FRP ) requirement 30 day prior first dose study medication last dose study medication completion followup contact . GSK modify list highly effective method avoid pregnancy FRP : . Contraceptive subdermal implant meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1percent rate failure per year , state product label . b . Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 percent rate failure per year , state product label . c. Oral Contraceptive , either combined progestogen alone . d. Injectable progestogen . e. Contraceptive vaginal ring . f. Percutaneous contraceptive patch . g. Male partner sterilization documentation azoospermia prior female subject 's entry study , male sole partner subject . h. Male condom combine vaginal spermicide ( foam , gel , film , cream , suppository ) . GSK modify list highly effective method avoid pregnancy FRP apply FRP sex partner , prefer usual lifestyle subject continue abstinent penilevaginal intercourse long term persistent basis . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Have current diagnosis chronic obstructive pulmonary disease ( COPD ) Have experience asthma exacerbation within 3 month Visit 1 low respiratory tract infection within 6 week Visit 1 . An exacerbation define worsen asthma require treatment rescue salbutamol . This include require use systemic inhaled corticosteroid /or emergency room visit hospitalisation . Other Concurrent Diseases : A subject must clinically significant , uncontrolled condition disease state ( severe cardiovascular disorder heart rhythm abnormality , diabetes mellitus , thyrotoxicosis , uncorrected hypokalaemia predisposition low level serum potassium ) , opinion investigator ( consultation GSK Medical Monitor require ) , would put safety subject risk study participation would confound interpretation result condition/disease exacerbate study . Please refer SERETIDE Product Label full list condition special warning precaution use . Currently take potent Cytochrome P450 3A4 ( CYP 3A4 ) inhibitor Currently take betablockers ( selective nonselective ) . Allergic salmeterol , fluticasone propionate norflurane ( HFA 134a ) excipients . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure 4 investigational medicinal product within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EVOHALER</keyword>
	<keyword>Asthma</keyword>
	<keyword>SERETIDE</keyword>
	<keyword>DISKUS Inhaler</keyword>
	<keyword>MDI</keyword>
</DOC>